$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞格非尼在标准治疗失败后胃肠道间质瘤患者中II期临床试验的长期随访结果
2025-10-19 11:44:20
Check Details
吉非替尼治疗结直肠癌
2025-10-19 11:44:20
Check Details
转移性结直肠癌患者可服用瑞格非尼或者TAS-102
2025-10-19 11:44:20
Check Details
瑞格非尼降低治疗转移性结直肠癌死亡风险
2025-10-19 11:44:20
Check Details
结直肠癌患者服用索拉非尼发生疾病进展后可服用瑞格非尼
2025-10-19 11:44:20
Check Details
瑞戈非尼耐受性的真实数据格外重要
2025-10-19 11:44:20
Check Details
瑞戈非尼的治疗数据以及安全性
2025-10-19 11:44:20
Check Details
转移性结直肠癌服用靶向药物瑞戈非尼的临床结果
2025-10-19 11:44:20
Check Details
难治性结直肠癌患者服用瑞格非尼可达到最高的有效性
2025-10-19 11:44:20
Check Details
结直肠癌患者在哪种情况先必须停止服用瑞格非尼
2025-10-19 11:44:20
Check Details
肝脏毒属性是直肠癌患者需要着重注意的事项之一
2025-10-19 11:44:20
Check Details
瑞格非尼诱导的转移性胃肠道间质瘤患者重度肝损伤:免疫抑制剂可以改善
2025-10-19 11:44:20
Check Details
1
2
...
1589
1590
1591
1592
1593
1594
1595
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
2
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
3
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
4
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
5
Complete Guide to Dosage and Dose Adjustment of Entrectinib
6
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
7
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
8
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
9
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
10
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
11
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer
12
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety